# IntellectiveBio Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/intellectivebio-co

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.intellectivebio.com
- Total disclosed funding: $74M
- Latest round: Series C (Aug 5, 2022)
- Investors on record: 9

## About

Established in 2018 and based in Suzhou, China, IntellectiveBio is a contract development and manufacture organization that focuses on biopharmaceutical process development and production. The company has built research and development laboratory, analysis and testing center, 200L pilot plant, 2000L GMP liquid production workshop, sterile preparation filling and lyophilization workshop in Suzhou Xiangcheng High-tech Zone, Industrial Park and Changshu High-tech Zone. There are more than 1000 employees in the company. In December 2019, the company was acquired drug production license.

The services provided by the company include commercial manufacturing, biologics development and other services. The company also provides developability assessment, recombinant protein expression and antibody humanization services. The company has seven CDMO technology platforms, covering GMP production platform, ADC platform, multiple culture platform, autonomous cell construction platform, drug-formation analysis platform, virus safety testing platform, and formulation development platform.

## Funding rounds

- Series C, Aug 5, 2022, $74M — Fuho Capital, Gaorong Ventures, Founder Securities, CIF Investment Fund Management, Tsing Song Capital, Win Harbor Capital
- Series B, Sep 7, 2021 — Legend Capital, Tsing Song Capital, BioTrack Capital
- Series A, Aug 26, 2021 — Legend Capital, Shiyu Capital
- Series B, Aug 26, 2021 — Legend Capital, BioTrack Capital, Shiyu Capital
- Series A, Dec 17, 2020 — Legend Capital, Tsing Song Capital, BioTrack Capital

## Investors

- Legend Capital — Series A, Series B
- Tsing Song Capital (https://capitalatlas.ai/funds/tsing-song-capital) — Series A, Series B, Series C
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series A, Series B
- Shiyu Capital (https://capitalatlas.ai/funds/shiyu-capital) — Series A, Series B
- Fuho Capital (https://capitalatlas.ai/funds/fuho-capital) — Series C
- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Series C
- Founder Securities — Series C
- CIF Investment Fund Management — Series C
- Win Harbor Capital (https://capitalatlas.ai/funds/win-harbor-capital) — Series C